MacroGenics, Inc. (NASDAQ: MGNX ) has been a story I've covered for quite a while now, with my most recent write-up focusing on the various factors stacking against the investment thesis. The story hasI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in ...

Financial Data and Key Metrics Changes - The company reported a cash runway extending through the first half of 2027, with $154 million in cash and cash equivalents as of March 31, 2025, and an additional $70 million from a transaction with Saggart Health Care Partners [5][36][38] - Over the last three years, the company has raised over $550 million from various partnerships and milestones, demonstrating a strong ability to finance operations through non-dilutive capital sources [38] Business Line Data and Key Metrics Changes - The company has three assets on the market: Margemza for HER2 positive breast cancer, TZEAL for type one diabetes, and Zynas, an anti-PD-1 antibody recently approved for frontline anal cancer [4][36] - The Lorigirlimab program is being developed for prostate cancer and ovarian cancer, with early clinical results showing a confirmed overall response rate (ORR) of 26% in castrate-resistant prostate cancer [12][15] Market Data and Key Metrics Changes - The ADC portfolio includes three molecules leveraging the Sinefix drug linker technology, targeting B7H3, with clinical validation established across multiple indications [21][22] - The company sees a competitive landscape for ADCs, expecting multiple players to establish a presence due to the broad range of indications for B7H3 [22] Company Strategy and Development Direction - The company is focused on developing innovative medicines through its proprietary platforms, including DART and Trident, and aims to translate early research insights into robust product candidates [3][4] - The company plans to advance additional molecules, including MGC030, with an IND submission expected in 2026, and aims to maintain a prolific research output with new INDs every 12 to 18 months [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory complexities and maintain a strong cash position, highlighting the importance of non-dilutive financing [5][38] - The company anticipates multiple inflection points and data updates over the next year, particularly for the Lorigirlimab program and ongoing ADC studies [34] Other Important Information - The company has a partnership with Gilead for a T cell engager molecule, which is currently in dose escalation, with Gilead holding an exclusive opt-in right [33] - The company is exploring accelerated approval paths for its ovarian cancer studies, particularly in aggressive forms of the disease [20] Q&A Session Summary Question: What is the status of the Lorigirlimab program? - The Lorigirlimab program has shown promising early results, with a confirmed ORR of 26% in prostate cancer, and the study is expected to provide updates later this year [12][15] Question: How does the company view the competitive landscape for ADCs? - The company believes there will be multiple players in the ADC market due to the expansive nature of indications for B7H3, and it is confident in its differentiating features [22] Question: What are the future plans for the pipeline? - The company plans to continue advancing its pipeline, with several IND submissions expected in the coming years, and aims to maintain a strong research output [34][36]

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under "Events ...

MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpo ...

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Macr ...

MacroGenics (MGNX) 2025 Conference May 08, 2025 10:30 AM ET Speaker0 Alright. Welcome back. My name is Silvan Turkan. I'm a senior analyst at Citizens covering precision medicines. Thanks so much for joining us at our healthcare conference. And now it's my pleasure to host MacroGenics. With me is Eric Rissen, COO of MacroGenics. Thank you so much. Speaker1 Great. Thank you, and appreciate the opportunity to present here today at the conference and talk about MacroGenics and all the milestones and upcoming e ...

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quar ...

Core Viewpoint - MacroGenics (MGNX) has experienced a significant decline of 48.7% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - MGNX has an RSI reading of 15.85, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for MGNX have increased by 10.2% over the last 30 days, which often correlates with price appreciation [7]. - MGNX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

MacroGenics (MGNX) Q4 2024 Earnings Call March 21, 2025 03:12 AM ET Company Participants James Karrels - Senior VP, CFO & Corporate SecretaryScott Koenig - President and CEOStephen Eck - Senior VP of Clinical Development & Chief Medical OfficerJonathan Chang - Senior Managing DirectorNick Lorusso - Vice PresidentJonathan Miller - Managing DirectorSilvan Türkcan - Managing DirectorMayank Mamtani - Senior Managing Director Conference Call Participants Peter Lawson - AnalystStephen Willey - Analyst Operator Go ...